Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia

Inclusion Criteria: * Performans status 0-2 * CP CML diagnosed since less than 3 months without previous Tyrosine Kinase Inhibitor (TKI) or interferon treatment * Adequate organic functions: * Total Bilirubin \< 1.5xUpper Normal Range (UNR). * Aspartate Amino Transferase (ASAT) and Alanine Amino Transferase (ALAT) \< 2.5xUNR. * Alkaline phosphatase ≤ 2.5xUNR * Amylase and lipase ≤ 1.5xUNR. * Creatininemia \< 1.5xUNR. * Biological blood standards : * Potassium ≥ Lower Normal Range (LNR) * Magnesium ≥ LNR. * Phosphorus ≥ LNR * Calcium ≥ LNR. * Negative pregnancy test within the last 7 days for women with childbearing potential. * Informed consent signed up * Compliance to tretament ensured, * Valid social insurance Exclusion Criteria: Prior TKI or interferon treatment for the CML * Contra-indication to IFN * Pregnancy, breast feeding * Human Immunodeficiency Virus positive, chronic hepatitis B or C. * Other BCR-ABL transcript than M-bcr * Cardiopathy defined as: * Left Ventricular Ejection Fraction (LVEF) \< 45%. * Left bundle branch block * Ventricular pacemaker. * Congenital prolonged QT * Past ventricular or significant auricular tachyarrythmia * Clinically significant bradycardia (\<50 per minute). * QTc (Fredericia) \> 450 ms (average on 3 Elektrokardiogramm (EKG)). * Myocardial infarction in the last 12 months. * Unstable angina within the last 12 months. * Other significant cardiac diseases. * Other uncontrolled severe disease (such as diabetes melittus etc…) * Other ongoing malignant disease. * Past history of congenital or acquired clinically significant bleeding disorder. * Previous radiotherapy ≥25% of bone marrow. * Serious surgery within the past 4 weeks * Investigational treatment within the last 30 days prior to day 1. * History of non compliance. * Cytochrome P450 3A4 (CYP3A4) inhibitors that could not be withdrawn or modified (such as erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil). * Severe gastro-intestinal disorders (such as gastric ulcer, uncontrolled nausea, malabsorption syndrome, small intestine resection, gastric shunt). * Hepatic, renal or pancreatic chronic disorder unrelated to CML * Recent history of acute pancreatitis within a year or history of chronic pancreatic disease . * Any concommittant treatment inducing QT prolongation.